MARSHALL WACE, LLP

Position in RCUS — Arcus Biosciences, Inc.

CIK 1318757 LONDON, X0

Position in RCUS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$81,247,039

+$515,908 QoQ

Shares Held

3,761,437

+11.0% QoQ

Ownership

2.99%

of shares outstanding

% of Portfolio

0.12%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

10 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,749,797,393 across 275 Biotechnology names. RCUS ranks #5 (3.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc. This page	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$81,247,039	3,761,437	+11.0%	Shares	Other	2026-05-15
2025-12-31	$80,731,131	3,387,794	+2923.4%	Shares	Other	2026-02-13
2025-03-31	$879,600	112,051	+928.4%	Shares	Other	2025-05-15
2022-12-31	$225,329	10,896	-38.7%	Shares	Other	2023-02-14
2022-09-30	$465,229	17,784	-92.2%	Shares	Other	2022-11-14
2022-06-30	$5,783,778	228,247	+27.8%	Shares	Other	2022-08-15
2022-03-31	$5,635,511	178,565	+30.1%	Shares	Other	2022-05-16
2021-03-31	$3,854,906	137,283	-16.1%	Shares	Sole	2021-05-17
2020-12-31	$4,248,250	163,646	+6320.0%	Shares	Sole	2021-02-16
2020-03-31	$35,380	2,549	—	Shares	Sole	2020-05-15
No filing history on record for this holder in this stock.